William Blair and BDA advise BMS on sale of its Couvet, Switzerland facility to WuXi AppTec
Agreed to divest Couvet, Switzerland facility to WuXi AppTec
BDA Partners is pleased to announce Bristol Myers Squibb (“BMS”), advised by William Blair in conjunction with BDA Partners, has agreed to divest its manufacturing facility in Couvet, Switzerland to WuXi STA, the CDMO subsidiary of WuXi AppTec. The value of the transaction is not disclosed.
BMS is a leading global pharma company. The Couvet site is a newly constructed, state-of-the-art manufacturing and packaging facility, with commercial-scale production capacity for capsule and tablet dosage forms. The facility was designed with industry leading energy efficiency and environmental standards and was constructed to accommodate future growth.
The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization (CDMO). WuXi STA will acquire the Couvet site’s operations and assets, which include the plant and equipment, as well as a workforce with technical capabilities and expertise. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.
For more information, please contact Andrew Huntley firstname.lastname@example.org, Managing Partner, and head of BDA’s Health sector banking team.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. www.bms.com
About WuXi STA
WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Control) solutions from preclinical to commercial uses. www.STApharma.com
About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps its partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize its vision that “every drug can be made and every disease can be treated.” www.wuxiapptec.com
BDA Partners is the global investment banking advisor for Asia. We are a premium provider of Asia-related advice to sophisticated clients globally, with 25 years’ experience advising on cross-border M&A, capital raising, and financial restructuring. We provide global reach with our teams in New York and London, and true regional depth through our seven Asian offices in Mumbai, Singapore, Ho Chi Minh City, Hong Kong, Shanghai, Seoul, and Tokyo. BDA has deep expertise in the Chemicals, Consumer & Retail, Health, Industrials, Services and Technology sectors. We work relentlessly to earn our clients’ trust by delivering insightful advice and outstanding outcomes.
BDA Partners has strategic partnerships with William Blair, a premier global investment banking business, and with DBJ (Development Bank of Japan), a Japanese Government-owned bank with US$150bn of assets.
US securities transactions are performed by BDA Partners’ affiliate, BDA Advisors Inc., a broker-dealer registered with the Securities and Exchange Commission (SEC). BDA Advisors Inc. is a member of the Financial Industry Regulatory Authority (FINRA) and SIPC. In the UK, BDA Partners is authorised and regulated by the Financial Conduct Authority (FCA). In Hong Kong, BDA Partners (HK) Ltd. is licensed and regulated by the Securities & Futures Commission (SFC) to conduct Type 1 and Type 4 regulated activities to professional investors.
Acquired Shenzhen Wikkon
Divested B Medical Systems to Azenta
Agreed to divest East Syracuse, New York facility to LOTTE Corporation
Sold minority stake to Quadria Capital
Investment from The Riverside Company
Acquired by MicroPort
Divested majority stake in OPV Pharmaceuticals to RV Healthcare
Divested majority stake to DCP Capital
Raised Series B round from ABC World Asia
Divested Escientia Life Sciences to Deccan Fine Chemicals
Divested significant stake in Kehua Bio-Engineering to Gree Real Estate
Divested LAP Laser to IK Investment Partners
Divested majority stake to The Longreach Group
Divested plant health business in Japan to Nisso
Divested The Ritedose Corporation to AGIC and Humanwell
Majority recapitalized by Galen Partners
Divested CMC Biologics to Asahi Glass